Replies to post #222990 on Biotech Values

[DewDiligence]

Andexxa is unique—the only approved FXa antidote; however, I don't think the market for it will be especially large.

[DewDiligence]

PTLA’s Bevyxxa sales continue to be negligible:

https://www.globenewswire.com/news-release/2019/05/08/1819333/0/en/Portola-Pharmaceuticals-Reports-First-Quarter-2019-Financial-Results-and-Provides-Corporate-Update.html

1Q19 Bevyxxa sales were $77,000 (not a typo).

Andexxa sales are not exactly on fire either: 1Q19 sales were $20.3M.